Cargando…

Repurposing of World-Approved Drugs for Potential Inhibition against Human Carbonic Anhydrase I: A Computational Study

Human carbonic anhydrases (hCAs) have enzymatic activities for reversible hydration of CO(2) and are acknowledged as promising targets for the treatment of various diseases. Using molecular docking and molecular dynamics simulation approaches, we hit three compounds of methyl 4-chloranyl-2-(phenylsu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Nannan, Jiang, Wanyun, Zhang, Puyu, Ma, Le, Chen, Junzhao, Zhang, Haiyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454238/ https://www.ncbi.nlm.nih.gov/pubmed/37628799 http://dx.doi.org/10.3390/ijms241612619

Ejemplares similares

Repurposing Drugs for Inhibition against ALDH2 via a 2D/3D Ligand-Based Similarity Search and Molecular Simulation
por: Jiang, Wanyun, et al.
Publicado: (2023)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021)

Virtual Screening of FDA-Approved Drugs for Enhanced Binding with Mitochondrial Aldehyde Dehydrogenase
por: Zhou, Boqian, et al.
Publicado: (2022)

Intracellular Binding/Unbinding Kinetics of Approved Drugs to Carbonic Anhydrase II Observed by in-Cell NMR
por: Luchinat, Enrico, et al.
Publicado: (2020)

Repurposing approved drugs on the pathway to novel therapies
por: Schein, Catherine H.
Publicado: (2019)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Carbonic Anhydrase Inhibitors as Novel Drugs against Mycobacterial β-Carbonic Anhydrases: An Update on In Vitro and In Vivo Studies
por: Aspatwar, Ashok, et al.
Publicado: (2018)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Drug repurposing strategy II: from approved drugs to agri-fungicide leads
por: An, Jun-Xia, et al.
Publicado: (2023)

In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
por: Mee-udorn, Pitchayathida, et al.
Publicado: (2023)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

Repurposing Approved Drugs for Sarcopenia Based on Transcriptomics Data in Humans
por: Liang, Shuang, et al.
Publicado: (2023)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

Drug repurposing strategy part 1: from approved drugs to agri-bactericides leads
por: Ma, Yue, et al.
Publicado: (2022)

Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia
por: Menteşe, Ahmet, et al.
Publicado: (2017)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes
por: Argan, Onur, et al.
Publicado: (2020)

Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
por: Flori, Lorenzo, et al.
Publicado: (2023)

Roles of Carbonic Anhydrases and Carbonic Anhydrase Related Proteins in Zebrafish
por: Aspatwar, Ashok, et al.
Publicado: (2022)

Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration
por: Hwang, Soyoung, et al.
Publicado: (2019)

Detection of autoantibodies against carbonic anhydrase I and II in the plasma of patients with gastric cancer
por: Mentese, Ahmet, et al.
Publicado: (2017)

Spontaneous regression of tumours. Possible cross reactivity of autoantibodies against carbonic anhydrase I
por: Lakota, Ján
Publicado: (2023)

Repurposing clinically approved cephalosporins for tuberculosis therapy
por: Ramón-García, Santiago, et al.
Publicado: (2016)

Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review
por: Andrade, Bruno Silva, et al.
Publicado: (2020)

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
por: Ahsan, Tamim, et al.
Publicado: (2021)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Repurposing the PDMA-approved drugs in Japan using an insect model of staphylococcal infection
por: Miyashita, Atsushi, et al.
Publicado: (2022)

A class of carbonic anhydrase I – selective activators
por: Licsandru, Erol, et al.
Publicado: (2016)

Advances in the computational landscape for repurposed drugs against COVID-19
por: Aronskyy, Illya, et al.
Publicado: (2021)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d1n4jb5t18n3lfl4tcbqe52uhn